Quote:

---

DOSAGE AND ADMINISTRATION
Recommended Dose
The recommended dose is 160 mg STIVARGA (four 40 mg tablets) taken orally once daily for the first 21 days of each 28-day cycle. Continue treatment until disease progression or unacceptable toxicity.

Take STIVARGA at the same time each day. Swallow tablet whole with water after alow-fat meal that contains less than 600 calories and less than 30% fat [see CLINICAL PHARMACOLOGY]. Do not take two doses of STIVARGA on the same day to make up for a missed dose from the previous day.

Dose Modifications
If dose modifications are required, reduce the dose in 40 mg (one tablet) increments; the lowest recommended daily dose of STIVARGA is 80 mg daily.

Interrupt STIVARGA for the following:

Grade2 hand-footskin reaction (HFSR)[palmar-plantar erythrodysesthesia syndrome (PPES)]that is recurrentor does not improve within 7 days despite dose reduction; interrupt therapy for a minimum of 7 days for Grade 3 HFSR
Symptomatic Grade 2 hypertension
Any Grade 3 or 4 adverse reaction
Worsening infection of any grade
Reduce the dose of STIVARGA to 120 mg:

For the first occurrence of Grade 2 HFSR of any duration
After recovery of any Grade 3 or 4 adverse reaction except infection
For Grade 3 aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevation, only resume if the potential benefit outweighs the risk of hepatotoxicity
Reduce the dose of STIVARGA to 80 mg:

For re-occurrence of Grade 2 HFSR at the 120 mg dose
After recovery of any Grade 3 or 4 adverse reaction at the 120 mg dose (except hepatotoxicity or infection)
Discontinue STIVARGA permanently for the following:

Failure to tolerate 80 mg dose
Any occurrence of AST or ALT more than 20 times the upper limit of normal (ULN)
Any occurrence of AST or ALT more than 3 times ULN with concurrent bilirubin more than 2 times ULN
Re-occurrence of AST or ALT more than 5 times ULN despite dose reduction to 120 mg
For any Grade 4 adverse reaction; only resume if the potential benefit outweighs the risks

---